Rocket Pharmaceuticals (DE:9IP1)
FRANKFURT:9IP1
Holding DE:9IP1?
Track your performance easily

Rocket Pharmaceuticals (9IP1) Income Statement

1 Followers

Rocket Pharmaceuticals Income Statement

Last quarter (Q3 2024), Rocket Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Rocket Pharmaceuticals's net income was $-66.72M. See Rocket Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
$ 2.70M$ 2.30M$ 1.20M$ 1.10M$ 1.10M-
Gross Profit
$ -2.70M$ -2.30M$ -1.20M$ -1.10M$ -1.10M-
Operating Expense
$ 275.94M$ 259.66M$ 223.84M$ 167.25M$ 134.30M$ 76.15M
Operating Income
$ -275.94M$ -259.66M$ -224.34M$ -167.25M$ -134.30M$ -76.15M
Net Non Operating Interest Income Expense
$ 6.49M$ -14.06M$ -1.98M$ 91.00K$ -4.82M$ -2.54M
Other Income Expense
$ -3.79M$ -700.00K$ -500.00K$ -1.00M$ 26.56M$ -100.00K
Pretax Income
$ -260.32M$ -245.59M$ -221.86M$ -169.07M$ -139.70M$ -77.52M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -260.32M$ -245.59M$ -221.86M$ -169.07M$ -139.70M$ -77.27M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 278.64M$ 259.66M$ 223.84M$ 168.35M$ 135.40M$ 76.15M
Net Income From Continuing And Discontinued Operation
$ -260.32M$ -245.59M$ -221.86M$ -169.07M$ -139.70M$ -77.27M
Normalized Income
$ -198.28M-----
Interest Expense
------
EBIT
$ -258.44M$ -243.72M$ -219.95M$ -163.18M$ -132.15M$ -71.56M
EBITDA
$ -251.28M$ -236.62M$ -213.69M$ -157.81M$ -125.90M$ -67.56M
Currency in USD

Rocket Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis